Cisplatin belongs to the group of platinum anti-tumour compounds widely used in the treatment of testicular and ovarian cancers and a variety of other solid tumours. The target for cisplatin is DNA, with which it binds efficiently to form a variety of monoadducts and cross-links, either between adjacent bases on the same strand of DNA or on opposing strands. These DNA lesions contribute to the cytotoxicity of cisplatin because they block DNA replication and promote cell death. In addition, several cellular proteins bind preferentially to cisplatin-damaged DNA, which could stimulate transduction pathways and ultimately signal apoptosis.One such protein is MutS, a component of the mismatch repair (MMR) machinery that removes aberrantly inserted bases from newly synthesized DNA following replication. Binding of MutS to cisplatin adducts is thought to result in a continuous, futile cycle of repair on the opposing DNA strand, ultimately leading to cell death. Loss of MMR in tumour cells confers cisplatin resistance, and there has been considerable investigation into the development of platinum compounds for use in cisplatin-resistant disease, and whose cytotoxicity is not circumvented by loss of MMR. Drugs that contain the bulky, non-polar diaminocyclohexane (DACH) ligand in place of the amine ligands of cisplatin appear to be promising in this respect. The DACH ligand, present in drugs such as oxaliplatin, is thought to have a different structural conformation in DNA than the corresponding cisplatin adduct, and perhaps provides a less recognizable structure for MutS.Zdraveski et al. [1xMutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA. Zdraveski, Z.Z. et al. J. Biol. Chem. 2002; 277: 1255–1260Crossref | PubMed | Scopus (75)See all References][1] have investigated this hypothesis by examining the binding of MutS to DNA-containing adducts formed by cisplatin and a DACH analogue. In vitro MutS binding assays revealed that purified MutS bound to cisplatin-modified DNA with twofold greater affinity than DNA modified with the DACH analogue. Sensitivity assays using Escherichia coli mutants corroborate these results; E. coli deficient in methylation, a process essential to MMR that distinguishes between newly synthesized and template DNA strands following replication, were twofold more sensitive to cell death by cisplatin than to DACH analogues. DACH-containing platinum drugs might therefore be less dependent on MMR-mediated cytotoxicity, and exert their cell killing effects by another mechanism, such as replication blockage. Indeed, the equal sensitivity of recombination-deficient mutants to both drugs suggest that the adducts formed by both cisplatin and DACH analogues block replication with equal efficiency.This study adds to the existing evidence that drugs that contain DACH ligands, such as oxaliplatin, might overcome the cisplatin resistance of MMR-deficient tumours. Furthermore, this study demonstrates the importance of structural differences in the structural conformation of DNA adducts formed by cytotoxic drugs, and supports the development of platinum drugs based on their coordination chemistry to combat drug resistance in human tumours.